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Abstract (word count 250) 
Background: Smoking is an important cardiovascular disease risk factor, but the mechanisms linking 
smoking to blood pressure are poorly understood.  
Methods and results: Data on 141,317 participants (62,666 never, 40,669 former, 37,982 current smokers) 
from 23 population-based studies were included in observational and Mendelian randomisation (MR) 
meta-analyses of the associations of smoking status and smoking heaviness with systolic and diastolic blood 
pressure (SBP, DBP), hypertension, and resting heart rate. For the MR analyses, a genetic variant 
rs16969968/rs1051730 was used as a proxy for smoking heaviness in current smokers. In observational 
analyses, current as compared with never smoking was associated with lower SBP, DBP, and lower 
hypertension risk, but with higher resting heart rate. In observational analyses amongst current smokers, 
one cigarette/day higher level of smoking heaviness was associated with higher (0.21 beats/minute; 95% CI 
0.19; 0.24) resting heart rate, and slightly higher DBP (0.05 mmHg; 95% CI 0.02; 0.08) and SBP (0.08 mmHg; 
95% CI 0.03; 0.13). However, in MR analyses amongst current smokers, while each smoking increasing allele 
of rs16969968/rs1051730 was associated with higher resting heart rate (0.36 beats/minute/allele; 95% CI 
0.18; 0.54), there was no strong association with DBP, SBP, or hypertension. This would suggest a 7 
beats/minute higher heart rate in those who smoke 20 cigarettes/day.  
Conclusions: This MR meta-analysis supports a causal association of smoking heaviness with higher level of 
resting heart rate, but not with blood pressure. These findings suggest that part of the cardiovascular risk of 
smoking may operate through increasing resting heart rate.  
Key words: blood pressure, hypertension, Mendelian randomization, resting heart rate, smoking 
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Introduction 
Smoking is a major risk factor for cardiovascular disease (CVD), but it is not clear by which mechanism 
smoking exerts its detrimental effects on CVD. Generally, epidemiological studies have reported lower 
blood pressure levels among current smokers compared with nonsmokers.1-14 On the other hand, smoking 
cessation has been reported to be followed by a decrease in blood pressure.15,16 Whether the apparent 
association between smoking and lower blood pressure is causal or can be explained by confounding by 
lifestyle or socioeconomic factors related to both smoking and blood pressure remains an open question. 
Furthermore, smoking is causally associated with lower body mass index (BMI),17 and higher level of 
adiposity is strongly associated with elevated blood pressure and is also considered a major risk factor for 
hypertension.18,19 Hence, there is a strong possibility that the lower blood pressure observed in smokers 
could be explained by lower body weight caused by smoking. Data from observational epidemiological 
studies also suggest that smoking is associated with higher level of resting heart rate..20 However, as for 
blood pressure, various confounding factors could explain this association.  
In Mendelian randomisation, causal relationships in human populations are examined by using genetic 
variants as proxies for exposures of interest. The principle of Mendelian randomisation relies on the basic 
laws of Mendelian genetics, segregation and independent assortment. When these principles hold at a 
population level, genetic variants will not be associated with the confounding factors that generally distort 
conventional observational studies.21 In addition, an outcome measure cannot alter the germline genotype 
that an individual is born with, so these analyses should not be affected by reverse causality. It can be 
applied in two ways – first, to establish whether an observational association is likely to be causal, and 
second, using formal instrumental variable methods, to more accurately estimate the magnitude of this 
causal effect. Here we focus on the former approach. 
 
A genetic variant, single nucleotide polymorphism (SNP), rs16969968, in the CHRNA5-CHRNA3-CHRNB4  
nicotinic receptor subunit gene cluster on chromosome 15 has demonstrated robust association with 
smoking heaviness within smokers.22-24 The rs16969968 variant is functional and leads to an amino acid 
change (D398N) in the nicotinic receptor alpha5 subunit protein.25 The minor allele of the rs16969968 SNP 
is associated with an average increase in smoking amount of one cigarette per day in smokers and is even 
more strongly associated with serum cotinine (a metabolite of nicotine) levels.24,26 Importantly, the 
rs16969968 has not been robustly associated with smoking status and may therefore primarily be used as a 
marker of smoking heaviness in smokers. It is in perfect linkage disequilibrium with another SNP, 
rs1051730, and the two SNPs therefore represent the same genetic signal and can be used interchangeably. 
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A large meta-analysis found that the minor allele of rs1051730 that increases smoking in current smokers is 
associated with lower BMI in current smokers, supporting the hypothesis that smoking is causally related to 
lower BMI.17 As expected, the effect of rs1051730 on BMI differed with smoking status; the negative effect 
was observed in current smokers but not in never smokers indicating that the association operate via 
smoking.17 
A study in 5,402 young Finnish adults examined the effects of rs1051730 on blood pressure.23 The smoking 
increasing allele of rs1051730 tended to associate with lower systolic and diastolic blood pressure (SBP and 
DBP) among current smokers, but there was no strong statistical evidence for these associations. 
Furthermore, there was no evidence of interaction between smoking status and rs1051730 genotype. 
Åsvold and colleagues looked at the association between rs1051730 and cardiovascular risk factors in the 
HUNT study.27 In the total population including never, former, and current smokers, they found that the 
smoking increasing allele of rs1051730 was associated with lower SBP, but there was no association with 
DBP. Unexpectedly, the association between the rs1051730 and SBP was mainly seen among never 
smokers and there was no interaction between genotype and smoking status in relation to SBP possibly due 
to lack of power to detect interaction effects. Thus, it is not yet fully established whether smoking-related 
genetic variants are associated with blood pressure.  
In this study, we investigated the associations between smoking and both blood pressure and resting heart 
rate, using both an observational and a Mendelian randomisation approach.  First, we meta-analysed a 
total of 23 population-based studies participating in the consortium for Causal Analysis Research in Tobacco 
and Alcohol (CARTA).28 Second, we examined the possible causal effects of smoking on blood pressure and 
resting heart rate by Mendelian randomization using rs16969968/rs1051730 as unconfounded and 
unbiased proxies of smoking heaviness in current smokers.  
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Methods 
Study Populations 
The study was carried out within the CARTA consortium 
(http://www.bris.ac.uk/expsych/research/brain/targ/research/collaborations/carta).28,29 We used data 
on individuals (aged ≥16 years) of self-reported European ancestry from 23 studies: the 1958 British birth 
cohort (1958 BC), the Avon Longitudinal Study of Parents and Children (ALSPAC, including both mothers 
and children),30,31 the British Regional Heart Study (BRHS), the Caerphilly Prospective Study (CaPS), Cohorte 
Lausannoise (CoLaus/PsyCoLaus), the Dan-monica10 study, the English Longitudinal Study of Ageing (ELSA), 
the National FINRISK Study (FINRISK), the Danish GEMINAKAR study (The importance of genes, familiar and 
common environment for the development of insulin resistance, abdominal adiposity and cardiovascular 
risk factors), Genetics of Overweight Young Adults (GOYA)  male, Generation Scotland: the Scottish Family 
Health Study (GS:SFHS), Health2006, the Helsinki Birth Cohort Study (HBCS), the Nord-Trøndelag health 
study (HUNT), Inter99, MIDSPAN Family Study, the Northern Finland Birth Cohorts (NFBC1966 and 
NFBC1986), the National Health and Nutrition Examination Survey (NHANES), the MRC National Survey of 
Health and Development (NSHD), the Netherlands Twin Registry (NTR), the PROspective Study of 
Pravastatin in the Elderly at Risk (PROSPER), and the Whitehall II study. All studies received ethics approval 
from local research ethics committees. Further details of these studies are provided in supplemental 
material. Descriptive statistics are presented in Supplemental Table S1. 
Genotype 
Within each study, individuals were genotyped for one of two SNPs in the CHRNA5-A3-B4 nicotinic receptor 
subunit gene cluster, rs16969968 or rs1051730. These SNPs are in perfect linkage disequilibrium with each 
other in Europeans (R2 = 1.00 in HapMap 3, http://hapmap.ncbi.nlm.nih.gov/) and therefore represent the 
same genetic signal. For studies with data available for both SNPs, the SNP that was genotyped in the 
largest number of participants was used. Details of genotyping methods within each study are provided in 
supplemental material.  
Measurements of blood pressure and heart rate 
Details on the methods used for measuring systolic (SBP) and diastolic (DBP) blood pressure (mmHg) and 
resting heart rate (beats per minute) in each study are provided in supplemental material. In cohorts where 
information about use of blood pressure lowering medication was available a constant was added to SBP 
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(15 mmHg) and DBP (10 mmHg) in subjects on blood pressure lowering medication as recommended by 
Tobin and colleagues.32 If this information was not available SBP and DBP were analysed as they were. 
Availability of information on blood pressure lowering medication in each study is provided in 
Supplemental Table S1. The following dichotomous outcomes were defined: 1) ‘hypertension’ as SBP >140 
mmHg or DBP >90 mmHg or taking blood pressure lowering medication,  2) ‘severe hypertension’ as SBP 
>160 mmHg or DBP >100 mmHg, or taking blood pressure lowering medication. Thus, participants taking 
blood pressure lowering medication were defined as having both hypertension and severe hypertension. 
BMI was calculated as weight/height2 (kg/m2). Age was calculated as years at the time of measurements of 
blood pressure and heart rate.  
Smoking status 
Individuals were classified as current, former, or never cigarette smokers. Where information on smoking 
frequency was available, current smokers were restricted to individuals smoking at least one cigarette per 
day. Smokers (occasional smokers) who reported smoking less frequently than this were excluded from 
analyses on smokers. Where information on pipe and cigar smoking was available, individuals reporting 
being current or former smokers of pipes or cigars but not cigarettes were excluded from all analyses.  
For studies with adolescent populations (ALSPAC children and NFBC 86), analyses were restricted to current 
daily smokers who reported smoking at least one cigarette per day (current smokers) and individuals who 
had never tried smoking (never smokers).  
Data on smoking heaviness in current smokers, measured as cigarettes smoked per day, were collected in 
most studies as a continuous variable and in a few studies as a categorical variable. For full details of the 
smoking measures collected within each study, see the supplemental material.  
Statistical analysis  
 Analyses were conducted within each contributing study using Stata and R software following the same 
pre-specified analysis protocol. The analysis protocol is available on the CARTA website: 
http://www.bris.ac.uk/expsych/research/brain/targ/research/collaborations/carta/ 
Scripts for data analyses and output for Stata and R were developed and made available to ensure uniform 
analyses and minimize errors in data extraction. Thus, analyses were restricted to individuals with full data 
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on blood pressure, heart rate, smoking status and rs16969968/rs1051730 genotype. Within each study, 
genotype frequencies were tested for deviation from Hardy Weinberg Equilibrium using a chi-squared test.  
In observational analyses, sex- and age-adjusted associations of smoking status (never, former, current) and 
smoking heaviness with continuous measures of SBP and DBP, and heart rate, were assessed using linear 
regression. For the smoking status analysis, never smokers were used as the reference group. The smoking 
heaviness analysis was restricted to current daily smokers, and beta estimates represent change in the 
outcome measure per additional cigarette consumed per day. Sex- and age-adjusted associations expressed 
as odds ratios (ORs) of smoking status (never, former, current) and smoking heaviness with binary 
measures of hypertension (‘hypertension’ and ‘severe hypertension’) were assessed using logistic 
regression. In additional analyses, the above models were further adjusted for BMI (continuous variable) to 
observe changes (if any) in the estimates for the effects of smoking.  
Mendelian randomisation analyses of the association between rs16969968/rs1051730 and continuous 
measures of blood pressure and heart rate were assessed using linear regression stratified by smoking 
status (never, former, current) and adjusted for age, and sex. Mendelian randomisation analyses of the 
association between rs16969968/rs1051730 and binary measures of hypertension (‘hypertension’ and 
‘severe hypertension’) were assessed using logistic regression stratified by smoking status (never, former, 
current) adjusted for age, and sex. An additive genetic model was assumed, so risk estimates represent the 
difference in risk of the outcome per additional copy of the minor (risk) allele. In additional analyses, the 
above models were further adjusted for BMI (continuous variable) observing changes in the estimates for 
the effects of the risk allele.  
Results from individual studies were meta-analysed in Stata (version 11) using the “metan” command. 
Results from observational analyses were combined by random effects model due to substantial 
heterogeneity (I2 > 50%). Results from Mendelian randomisation analyses were combined in a fixed effects 
model and the Cochran Q statistic was used to test for heterogeneity between genotype and smoking 
status in relation to the outcome measures.  
 
 
  
  14 
 
Results 
Descriptive statistics 
In total, data on 141,317 iindividuals were available for analysis, including 62,666 never smokers, 40,669 
former smokers, and 37,982 current smokers. Overall, 49% of the combined study population was male. 
The median age within the contributing studies ranged from 16 to 75 years. Descriptive statistics for each 
of the study populations are found in the Supplemental Table S1. Minor allele frequency for 
rs16969968/rs1051730 ranged between 0.29 and 0.36 (Supplemental Table S2). There was no strong 
evidence for deviation from Hardy Weinberg Equilibrium in any of the studies (p-values all ≥ 0.1) 
(Supplemental Table S2). 
Observational analysis  
The meta-analysed estimates of the age- and sex-adjusted associations of smoking status (never, former, 
current smoking) with SBP, DBP, and resting heart rate are shown in Figure 1. Study-specific estimates are 
shown in supplemental material. Current as compared with never smoking was associated with lower SBP (-
2.40 mmHg; 95% CI -3.39; -1.41) and DBP (-1.93 mmHg; 95% CI -2.72; -1.15). Accordingly, current as 
compared with never smoking was associated with a lower risk of hypertension (OR 0.78; 95% CI: 0.70; 
0.88) and severe hypertension (OR 0.79; 95% CI: 0.66; 0.94) (Figure 2).  
The above associations were attenuated, but remained, when further adjusted for BMI (Supplemental 
Figures S1 and S2). For example, after additional adjustment for BMI, current as compared with never 
smoking was associated with a lower risk of hypertension (OR 0.84; 95% CI: 0.73; 0.94) and severe 
hypertension (OR 0.85; 95% CI: 0.72; 1.01) (Supplemental Figure S2). 
Current as compared with never smoking was associated with 1.93 beats per minute (95% CI: 0.97; 2.89) 
higher resting heart rate (Figure 1) and this association was not attenuated by adjustment for BMI 
(Supplemental Figure S1).  
The analysis of smoking heaviness (performed only in current smokers) showed that higher level of smoking 
heaviness was associated with slightly higher levels of SBP and DBP (Figure 3). In age- and sex-adjusted 
analyses, one cigarette per day higher level of smoking heaviness was associated with a 0.08 (95% CI: 0.03; 
0.13) and 0.05 (95% CI: 0.02; 0.08) mmHg higher SBP and DBP, respectively. These associations attenuated 
after further adjustment for BMI (Figure S3). One cigarette per day higher level of smoking heaviness was 
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associated with a 0.21 (95% CI: 0.19; 0.24) beats per minute higher level of resting heart rate (Figure 3), and 
this association was not attenuated by adjustment for BMI (Supplemental Figure S3).  
Mendelian randomization analysis 
In meta-analyses stratified by smoking status, there was no strong evidence that rs16969968/rs1051730 
was associated with either continuous measures of blood pressure (Table 1)(Figure 4) or with binary 
measures of hypertension (hypertension and severe hypertension) (Table 1)(Supplemental Figure S4). 
Associations were closer to the null after adjustment for BMI (Supplemental Figures S5 and S6). There was 
no evidence that the effect of the CHRNA5-A3-B4 variant differed between never, former and current 
smokers (p-values for heterogeneity from Cochran Q test all >= 0.1). 
In contrast, in current smokers, the smoking increasing allele of rs16969968/rs1051730 was associated with 
a 0.36 (95% CI 0.18; 0.54) beats per minute higher heart rate per allele (Table 1)(Figure 4). This estimate 
was 0.39 (95% CI 0.21; 0.57)) after additional adjustment for BMI (Supplemental Figure S5). In addition, 
there was evidence of interaction (p-value for heterogeneity from Cochran Q test 0.003) between smoking 
status and the CHRNA5-A3-B4 variant in age, sex and BMI-adjusted analyses lending further support to a 
causal effect of smoking on resting heart rate.  
The results of observational and Mendelian Randomization analyses stratified by two smoking status 
categories (never and ever smokers) were in line with the analyses stratified by three smoking categories 
(never, former, and current smokers) (data not shown).  
Additionally, sensitivity analyses were performed excluding each of the following studies: HUNT, ALSPAC 
children, and Prosper. The reasons for this were the large number of participants contributed by one study 
(HUNT), relatedness between participants (mothers and children in ALSPAC), and results being outliers 
(Prosper). These analyses yielded generally results similar to results based on all studies. However, when 
excluding the HUNT study, the association of the smoking increasing allele of rs16969968/rs1051730 with 
resting heart rate in current smokers attenuated and became statistically insignificant.  
Finally, we investigated the association of the smoking increasing allele of rs16969968/rs1051730 with 
smoking status and smoking heaviness. In current smokers, the smoking increasing allele of 
rs16969968/rs1051730 was associated with 0.9 cigarettes/day/allele increase in smoking heaviness (Figure 
5). Our results confirmed previous findings in that the smoking increasing allele is not associated with 
smoking initiation (the allele is not associated with ever versus never smoking), but may be associated with 
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smoking cessation (the allele is significantly associated with current versus former smoking) (Supplemental 
Figure S7).
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Discussion 
We performed a meta-analysis of 23 population-based studies including a total of 141,317 individuals, 
using both observational and Mendelian randomisation analyses. In observational analyses, we found that 
current smoking is associated with lower blood pressure and lower prevalence of hypertension. However, 
observational and Mendelian randomisation analyses did not support a causal association between 
smoking heaviness in current smokers and blood pressure. In contrast, both observational and Mendelian 
randomisation analyses consistently suggested that smoking heaviness is causally related to increasing 
resting heart rate amongst smokers.  
In our meta-analyses, the risk estimate for the effect of rs16969968/rs1051730 on blood pressure in 
current smokers was close to the null, with the confidence interval overlapping the null. Thus, the 
Mendelian randomisation analysis did not support a causal effect of smoking heaviness on blood pressure. 
It should be stressed that the unadjusted analysis captures the overall effect of smoking on blood pressure.  
Given evidence from previous Mendelian randomisation studies that smoking reduces BMI, and BMI causes 
higher blood pressure, we might have expected to see a negative association between the smoking 
increasing allele and blood pressure in current smokers, unless smoking increases blood pressure through 
other pathways. There was some indication that adjustment for BMI in our Mendelian randomisation 
analyses attenuated the estimates for the effects of the smoking increasing allele among current smokers 
even more towards the null, an observation that may suggest that any potential effect of smoking on blood 
pressure would be mediated through the BMI-decreasing effect of smoking.17 It should be stressed, that if 
BMI acts as a mediator, adjustment for BMI would be inappropriate and caution should be exercised when 
interpreting the BMI adjusted results. Future studies could employ a double Mendelian randomization 
approach using genetic makers of both smoking and BMI.  
Amongst current smokers, results of our Mendelian randomisation analysis supported that smoking 
heaviness is causally associated with increasing resting heart rate. These results thus corroborate results of 
our observational analysis and are furthermore in line with studies showing that resting heart rate tends to 
decrease following smoking cessation.16,33,34 The mechanisms by which smoking increases resting heart rate 
are not clear. Human experimental studies show that administration of nicotine increases resting heart rate 
and that this is an acute effect.35,36 Thus, when nicotine is administered intravenously the heart rate 
increasing effect peaks within the first minute after administration.36 Interestingly, it has been observed 
that reductions in hospital admissions with acute myocardial infarction following smoking regulation and 
bans in public places appear to have a surprisingly rapid onset.37   
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The clinical implications of smoking-induced higher resting heart rate are not clear. However, considering 
the well-documented detrimental effects of smoking on risk of cardiovascular disease and our finding that 
this might not involve a strong direct effect on blood pressure, it may be speculated that more attention 
should be paid to resting heart rate as a marker of cardiovascular health and risk prediction.38 Several 
studies have shown that resting heart rate is a predictor of cardiovascular events even after controlling for 
other cardiovascular risk factors such as blood pressure.39-44 Of potential relevance is that heart-rate 
lowering drugs improve long-term survival of patients with myocardial infarction.45 Our results roughly 
translated estimate that someone smoking 20 cigarettes per day could increase their resting heart rate by 
around 7 beats per min, and vice versa that someone stopping smoking could have this meaningful 
reduction in HR.   
The minor allele of the rs16969968/rs1051730 is known to be associated with smoking heaviness by 
approximately 1 cigarette per day per copy of the allele in current smokers,46 and we observed a 0.36 (95% 
CI 0.18; 0.54) beats per minute higher resting heart rate per one extra copy of the smoking increasing allele 
in current smokers (Figure 4). Using the CHRNA5-A3-B4 variant (rs16969968/rs1051730) as an instrument 
for tobacco exposure may be advantageous compared to using a self-reported measure of tobacco 
exposure. Firstly, self-reported tobacco use is likely subject to some degree of misclassification and 
reporting bias. Secondly, self-reported tobacco consumption does not take into account variation in 
smoking topography, such as the amount of a cigarette an individual smokes or the depth of inhalation.24 
Thirdly, the CHRNA5-A3-B4 variant is an instrument for lifetime cumulated tobacco exposure, and this is 
not fully captured by cigarettes per day. In further support of the genetic variant being a better measure of 
smoking heaviness, it has been shown that rs16969968/rs1051730 explains more of the variance (4%) in 
serum cotinine, a biomarker of tobacco exposure, than in self-reported number of cigarettes per day 
(1%)24,26. Notably, the effect (0.21 beats per minute increase per cigarette per day) of smoking heaviness on 
resting heart rate observed in our observational analyses based on self-reported smoking habits was 
smaller than indicated by the Mendelian randomisation analyses, a finding that is consistent with the idea 
that the rs16969968/rs1051730 SNP is a more accurate marker of smoking heaviness than self-reports. Of 
note, it has previously been shown that the use of instrumental variable analysis in Mendelian 
Randomisation studies estimate the magnitude of any causal effect of cigarette smoking, where measured 
self-reported cigarette consumption is used as the exposure, is likely inappropriate and may lead to biased 
estimates.47 
We would not expect to see an effect of rs16969968/rs1051730 on resting heart rate in never smokers, 
because the variant cannot be associated with smoking heaviness within these individuals without any 
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exposure. Thus, this group can be used to test the assumption of no pleiotrophy (i.e. that the gene affects 
only one exposure) in Mendelian randomisation analyses. Thus, our observation that there was no clear 
statistical evidence for an association of the rs16969968/rs1051730 variant with heart rate in never 
smokers, and that we observed statistical evidence of heterogeneity of the effect of the variant between 
smoking categories, lends further support to the notion that smoking is causally related to higher resting 
heart rate.  
The principle of Mendelian randomization is based of assumptions, e.g. a) the genetic marker is associated 
with the exposure, b) the genetic marker is independent of the outcome given the exposure and all 
confounders (pleitrophy, see above), and c) the genetic marker is independent of factors that confound the 
exposure-outcome relationship. It should be recognized that these assumptions may not all be easy to 
evaluate.  
Stratification of Mendelian randomisation analyses may induce collider bias, if the instrument is predictive 
of the stratification variable.48 We do not think that this is a major concern as our instrument 
rs16969968/rs1051730 is primarily a genetic variant for smoking heaviness within smokers and there is no 
clear evidence that it is associated with smoking initiation (i.e. being an ever versus a never smoker). It  
does show some evidence for an association with smoking cessation,49 but analyses performed in ever 
smokers yielded results similar to analyses performed in current smokers. The rs16969968/rs1051730 
variant has been used in a similar way (i.e. stratified on smoking status) in a number of other Mendelian 
Randomisation studies to demonstrate the expected causal associations of smoking with increased all-
cause mortality,50 decreased lung function,51 and body mass index. The fact that stratification by smoking 
status has been used to show that smoking is, as expected, causally related these phenotypes, supports our 
view that this approach is appropriate.    
Conclusions 
This large Mendelian randomization meta-analysis suggests that smoking is causally related to higher level 
of resting heart rate, but not to alterations in blood pressure and risk of hypertension. These findings are 
consistent with the hypothesis that smoking exerts its detrimental effects on cardiovascular disease at least 
partly via increasing resting heart rate.  
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Table 1: Mendelian randomization meta-analysis: results of meta-analysed estimates of the association of the smoking 
increasing allele of rs16969968/rs1051730 with continuous measures of blood pressure, binary measures of 
hypertension (hypertension and severe hypertension), and the continuous measure of resting heart rate. Results were 
stratified by smoking status.  
 Never smokers Former smokers Current smokers 
Systolic blood pressure                      
beta-coefficient*  (95% CI); mmHg/allele 
-0.07 (-0.28; 0.13) 
P = 0.479 
-0.03 (-0.31; 0.25)  
P = 0.824 
-0.20 (-0.46; 0.06)     
P = 0.136 
    
Diastolic blood pressure                             
beta-coefficient*  (95% CI); mmHg/allele 
0.01 (-0.12; 0.14) 
P = 0.879 
0.08 (-0.09; 0.26)   
P = 0.331 
-0.15 (-0.32; 0.02)     
P = 0.079 
    
Hypertension                                               
Odds ratio* (95% CI) per allele 
1.00 (0.97; 1.03)  
P = 0.923 
1.00 (0.96; 1.03)     
P = 0.811 
0.98 (0.95; 1.02)        
P = 0.277  
    
Severe hypertension  
Odds ratio* (95% CI) per allele 
1.02 (0.98; 1.05)  
P = 0.362 
1.01 (0.97; 1.05)     
P = 0.543 
0.96 (0.92; 1.00)        
P = 0.061 
    
Resting heart rate 
beta-coefficient* (95% CI); beats/minute/allele 
0.03 (-0.11; 0.17) 
P = 0.686 
0.15 (-0.03; 0.33)   
P = 0.109 
0.36 (0.18; 0.54)        
P < 0.001 † 
 
    
* associations have been adjusted for sex and age by linear (continuous outcomes) or logistic (binary outcomes) 
regression 
† Bonferroni-adjusted (15 tests) P-value was 0.001 
CI confidence interval 
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Figure 1. Association of smoking status with systolic blood pressure (SBP) and diastolic blood pressure (DBP), and resting heart rate (RHR). Former and current smoking 
status are compared to never smoking status; the difference was estimated by linear regression adjusted for sex and age.  
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Figure 2. Association of smoking status with hypertension and severe hypertension. Former and current smoking status are compared to never smoking status; the 
difference was estimated by logistic regression adjusted for sex and age. OR, Odds ratio.  
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Figure 3. Association of smoking heaviness in current smokers with systolic blood pressure (SBP) and diastolic blood pressure (DBP) and resting heart rate (RHR). The 
difference per one cigarette per day increase in smoking heaviness was estimated by linear regression adjusted for sex and age.  
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Figure 4. Mendelian randomisation analysis of the association of the smoking increasing allele (minor allele) of rs1051730/rs16969968 with systolic blood pressure 
(SBP) and diastolic blood pressure (DBP) and resting heart rate (RHR). Analyses were stratified by smoking status (current, former, and never smoking). The difference 
per one allele was estimated by linear regression adjusted for sex and age. Overall test for heterogeneity by smoking status: SBP: P=0.656; DBP: P=0.138; RHR: P=0.015; 
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Figure 5. Mendelian randomisation analysis of the association of the smoking increasing allele (minor allele) of rs1051730/rs16969968 with smoking heaviness in current smokers. 
The difference (increase in smoking quantity) per one allele was estimated by linear regression adjusted for sex and age.  
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